StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB – Free Report) in a research note issued to investors on Monday morning. The brokerage issued a buy rating on the stock.
Trinity Biotech Stock Performance
Shares of NASDAQ:TRIB opened at $2.85 on Monday. The firm has a 50 day simple moving average of $2.47 and a 200 day simple moving average of $2.23. Trinity Biotech has a 52 week low of $1.49 and a 52 week high of $4.95. The company has a market cap of $21.68 million, a PE ratio of -1.02 and a beta of 1.31.
Trinity Biotech (NASDAQ:TRIB – Get Free Report) last posted its quarterly earnings data on Thursday, May 23rd. The company reported ($0.37) EPS for the quarter. The company had revenue of $14.70 million for the quarter. On average, equities analysts predict that Trinity Biotech will post -2.17 earnings per share for the current year.
Trinity Biotech Company Profile
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Featured Articles
- Five stocks we like better than Trinity Biotech
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- First Solar Stock: The Dawn of a New Rally in Share Prices
- 10 Best Airline Stocks to Buy
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Why is the Ex-Dividend Date Significant to Investors?
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.